Malignant gliomas radiation therapy

Results with Surgery and Radiation Therapy Trials of Chemotherapeutic Agents Recursive Partitioning Analysis Specific Therapy Considerations in non-GBM Malignant Gliomas Radiation Therapy Strategies Novel Chemotherapeutic Agents Future Directions References... 

Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a Phase I/II trial of hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas Radiation Therapy Oncology Group study 83-02. Cancer 1996 77 1535-1543. 

Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993 85 704-710. 

Staba MJ, Mauceri HJ, Kufe DW, et al. Adenoviral TNF-a gene therapy and radiation damage tumor vasculature in a human malignant glioma xenografts. Gene Ther 1998 5 293-300. 

Brem H, Ewend MG, Piantadosi S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas phase I trial. J Neurooncol 1995 26 111-123. 

Temozolomide (Temodar) is a recently introduced tria-zene that has significant activity in patients with malignant gliomas, where it is the standard agent in combination with radiation therapy. Temozolomide, like dacarbazine, forms the methylating metabolite MTIC and kills cells in all phases of the cell cycle. 

Phase I-II trial results confirmed Ghadel as a safe treatment option for patients newly diagnosed with malignant gliomas who received post-operative radiation therapy. The study was free of perioperative mortality, and furnished no evidence of polymer-induced local or systemic toxicity. Of 22 patients, 21 received a pathological diagnosis of GBM median survival was 44 weeks from implantation with four patients surviving beyond 18 months. 

Vogelbaum MA, Sampson JH, Kunwar S et al. (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas phase 1 study of final safety results. Neurosurgery 61 1031-1037... 

Hurley J, Doliny P, Reis I, et al (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24 1831-1838 Jones B, Sanghera P (2007) Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 68 441-448... 

Haritz, D., Gabel, D., and Huiskamp, R. 1994. Clinical phase-I study of NajE HuSH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT). Int. J. Radiation Oncology Biol. Phys. 28 1175-81. 

---